In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography

Positron emission tomography (PET) has been used extensively to evaluate the neuropathology of Alzheimer's disease (AD) in vivo. Radiotracers directed toward the amyloid deposition such as [F-18]-FDDNP (2-(1-{6-[(2-[F] Fluoroethyl)(methyl) amino]-2-naphthyl} ethylidene) malononitrile) and [C-11]-PIB (Pitts-burg compound B) have shown exceptional value in animal models and AD patients. Previously, the glucose analogue [F-18]-FDG (2-[(18)F] fluorodeoxyglucose) allowed researchers and clinicians to evaluate the brain glucose consumption and proved its utility for the early diagnosis and the monitoring of the progression of AD. Animal models of AD are based on the transgenic expression of different human mutant genes linked to familial AD. The novel transgenic 5XFAD mouse containing 5 mutated genes in its genome has been proposed as an AD model with rapid and massive cerebral amyloid deposition. PET studies performed with animal-dedicated scanners indicate that PET with amyloid-targeted radiotracers can detect the pathological amyloid deposition in transgenic mice and rats. However, in other studies no differences were found between transgenic mice and their wild type littermates. We sought to investigate in 5XFAD mice if the radiotracers [C-11]-PIB, and [F-18]-Florbetapir could quantify the amyloid deposition in vivo and if [F-18]-FDG could do so with regard to glucose consumption. We found that 5XFAD animals presented higher cerebral binding of [F-18]-Florbetapir, [C-11]-PIB, and [F-18]-FDG. These results support the use of amyloid PET radiotracers for the evaluation of AD animal models. Probably, the increased uptake observed with [F-18]-FDG is a consequence of glial activation that occurs in 5XFAD mice. (C) 2013 Elsevier Inc. All rights reserved.